THERAPEUTIC FRONTIERS

Therapeutic Frontiers (TF) offers a radical alternative approach to clinical trials in asthma and COPD exacerbations and respiratory infection, providing the human rhinovirus experimental-infection model for the study of NMEs. Exacerbations of asthma and COPD, primarily triggered by respiratory viral infections, are the major cause of both the morbidity and mortality associated with the diseases, representing a significant unmet medical need.